Ona Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Ona Therapeutics's estimated annual revenue is currently $7M per year.
- Ona Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Ona Therapeutics has 45 Employees.
- Ona Therapeutics grew their employee count by 32% last year.
Ona Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Chief Medical Officer (Consultant) | Reveal Email/Phone |
3 | BI & BD Manager | Reveal Email/Phone |
4 | Executive Assistant to CEO | Reveal Email/Phone |
5 | PHD Student | Reveal Email/Phone |
6 | Research assistant | Reveal Email/Phone |
Ona Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7.8M | 50 | N/A | N/A | N/A |
#2 | $1.1M | 7 | N/A | N/A | N/A |
#3 | $7.1M | 46 | N/A | N/A | N/A |
#4 | $57.4M | 370 | 19% | N/A | N/A |
#5 | $11.5M | 74 | 10% | N/A | N/A |
#6 | $56.9M | 367 | 25% | N/A | N/A |
#7 | $2M | 13 | -13% | N/A | N/A |
#8 | $2.6M | 17 | -29% | N/A | N/A |
#9 | $5.1M | 33 | 22% | N/A | N/A |
#10 | $7M | 45 | 32% | N/A | N/A |
What Is Ona Therapeutics?
Ona Therapeutics is a biotech company, spin-off of ICREA and IRB, specialized in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism.
keywords:N/A
N/A
Total Funding
45
Number of Employees
$7M
Revenue (est)
32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ona Therapeutics News
2022-04-20 - -$0.24 Earnings Per Share Expected for Context Therapeutics ...
Equities research analysts expect Context Therapeutics Inc. ... Its lead product candidate is onapristone extended release (ONA-XR),...
2022-04-06 - Context Therapeutics® Announces Encouraging Preclinical Data from Two
Programs to be Presented at the American Association for Cancer Research
(AACR) Annual Meeting 2022
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models.
Other Companies in Barcelona
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.3M | 45 | 5% | N/A |
#2 | $5M | 45 | -2% | N/A |
#3 | $7M | 45 | 55% | N/A |
#4 | $7.7M | 46 | -49% | N/A |
#5 | $5.2M | 46 | N/A | N/A |